COMP <GO>
HALO vs JNJ // EV/EBITDA & P/E VALUATION
Halozyme Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HALO 5
— JNJ 9
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $130.91 (-0.21%) • MKT CAP: $14.89B
valuation
35.6x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HALO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.60% | 67.90% | +15.70 | HALO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.00% | 25.50% | -7.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 35.6x | 18.5x | +17.10 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.33% | 2.97% | +1.36 | HALO | /fcf-yield <GO> |
| Operating Margin | 33.60% | 34.70% | -1.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 22.70% | 28.50% | -5.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 37.60% | 6.00% | +31.60 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.11 | 5.59 | -0.48 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | HALO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 78.7 | 60.4 | +18.37 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.08 | -0.20 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.5x | 23.0x | +16.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.89B | $662.49B | -$647.60B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HALO REV | JNJ REV | HALO GROSS % | JNJ GROSS % | HALO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $94.19B | 83.6% | 67.9% | $644.6M | $19.70B |
| FY 2024 | $1.02B | $88.82B | 84.3% | 69.1% | $468.4M | $19.84B |
| FY 2023 | $829.3M | $85.16B | 44.0% | 44.0% | $351.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
JNJ // BETA 1.08